Nemolizumab for treating prurigo nodularis [ID6451]

  • In development
  • GID-TA11566
  • Expected publication date: TBC

NICE has paused the evaluation of nemolizumab for treating prurigo nodularis [ID6451] because the company and NHSE have commenced commercial discussions

Following a request from the company, the timelines for this evaluation have been revised. The second committee meeting will now be held on 15 April 2026